Anzeige
Mehr »
Login
Montag, 06.02.2023 Börsentäglich über 12.000 News von 679 internationalen Medien
Tatsächlich Wiederholung des 7.000-Prozent-Erfolgs?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JBKZ ISIN: GB00BF5G6K95 Ticker-Symbol: RQE1 
Stuttgart
06.02.23
09:19 Uhr
0,120 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
RENEURON GROUP PLC Chart 1 Jahr
5-Tage-Chart
RENEURON GROUP PLC 5-Tage-Chart

Aktuelle News zur RENEURON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.01.ReNeuron Group plc: Director/PDMR Shareholding-
24.01.Director dealings: Reneuron CFO makes share purchase1
24.01.ReNeuron Group plc: Share Purchase by Chief Financial Officer-
23.01.ReNeuron Group plc: Share Purchase by Executive Chairman-
19.01.IN BRIEF: ReNeuron reduces headcount by 40%; to focus on CustomEX data1
19.01.ReNeuron lays off 40% of staff after funding failure, buying time to execute exosome pivot1
RENEURON Aktie jetzt für 0€ handeln
19.01.ReNeuron Group plc: Company restructuring update-
03.01.Restructuring announced at ReNeuron as another CEO resigns-
03.01.ReNeuron Chair Iain Ross moves to executive chair as CEO departs-
03.01.ReNeuron Group plc: Total Voting Rights-
03.01.ReNeuron Group plc: Directorate Change-
12.12.22ReNeuron Group plc: Holding(s) in Company-
09.12.22ReNeuron Group - Encouraging data for iPSCs opens potential243ReNeuron Group has presented encouraging preclinical data surrounding the company's conditionally immortalised induced pluripotent stem cell (CI iPSC) line. The results show that, using the group's...
► Artikel lesen
08.12.22ReNeuron Group plc: Positive iPSC data presented at conference2
07.12.22Edison Group: ReNeuron Group: Pushing on with CustomEx in H123272LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k...
► Artikel lesen
06.12.22ReNeuron Group - Pushing on with CustomEx in H123252With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income...
► Artikel lesen
02.12.22ReNeuron shares tumble after first-half results2
02.12.22ReNeuron loss narrows amid lower costs and surging revenue1
02.12.22ReNeuron Group HY Loss Narrows1
02.12.22ReNeuron Group plc: Interim Results-
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1